CDP-12: [Product] 21 Impact Labs Partnership

Summary

The goal of this proposal is to authorize Cerebrum DAO to enter into a Product Partnership with 21 Impact Labs, developer of the xponetiq mobile app. xponetiq is grounded in licensed evidence-based neuroscience and has been designed and developed to support the brain health of individual consumers throughout their lives. The partnership will allow Cerebrum to bring the xponetiq app to the Cerebrum community and establish a knowledge and data sharing strategy between the organizations to further Cerebrum’s goal in addressing brain health and developing neurodegeneration solutions for society.

21 Impact Labs

21 Impact Labs (“21 Impact”) is the developer of the xponetiq app for brain health, based on an exclusive license to longitudinal research developed and validated by the University of Texas at Dallas Center for Brain Health, makes exercising brain healthy habits a daily norm for millions, reducing the noise in one’s life, increasing quality time, and achieving peak performance.

Cerebrum DAO

Cerebrum DAO (“Cerebrum”) is a global network-based organization that is funded and governed by its members via its NEURON token. It seeks to accelerate solutions to brain health and preventions, and cures for brain diseases by deploying its capital and coordinating its global talent to source, fund, develop, and deliver novel evidence-based solutions for human use.

The rationale for entering into a partnership between Cerebrum and 21 Impact is to:

(a) bring the xponetiq brain health app to the Cerebrum community, providing longitudinal metrics on brain health assessment, etc;

(b) expand the use of the NEURON token from governance to a data sharing utility, so that brain health assessment data can be provided by users in exchange for sharing their data;

(c) implement a token staking utility strategy for NEURON such that staking NEURON can be done in exchange for discounts on access to products such as xponetiq;

(d) setup a gateway for consumers to find and participate in the best, evidence-based products and solutions for brain health globally.

Upon approval of this CDP, the Cerebrum will enter into a partnership negotiation phase to bring xponetiq to the Cerebrum community (NEURON holders).

Considerations

The following are the core considerations for this proposal:

Partnership Values Alignment

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS), pose significant challenges to our society. These conditions are progressive, leading to loss of neuron function, motor dysfunction, cognitive decline,, and ultimately, a diminished quality of life and death. As our population ages, the prevalence of neurodegenerative disorders is increasing, creating a pressing need for empowering people with primary prevention strategies and accelerating solutions to early diagnosis, treatment, and care. Despite advances in research, a lack of effective therapies remains that can halt, slow down, or reverse disease progression and how interventions can be supported through behavior modification. Cerebrum and 21 Impact are, therefore, seeking a Collaboration Framework to work together and have a positive impact on neurodegenerative disease, combining the strengths of both organizations for the benefit of society.

...

Please visit the following link to view the full proposal, as the proposal content exceeds Discord Forum's character limit: https://docs.google.com/document/d/1MTlBIfbUeOWG6RVi4PLrXivWHN-3vRRXaZUn7yNnHGs/edit?usp=sharing